<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01335451</url>
  </required_header>
  <id_info>
    <org_study_id>D3030C00004</org_study_id>
    <nct_id>NCT01335451</nct_id>
  </id_info>
  <brief_title>Assess the Safety, Tolerability and Pharmacokinetics of AZD5213 After Single and Multiple Ascending Oral Doses in Healthy Young and Elderly Japanese Subjects</brief_title>
  <official_title>A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5213 After Oral Administration of Single and Multiple Ascending Doses in Healthy Young and Elderly J</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of
      AZD5213 in healthy young and elderly Japanese subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety and tolerability of AZD5213 by assessment of adverse event, vital signs, laboratory parameters and electrocardiograms (ECGs).</measure>
    <time_frame>Range of Days 1-12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the PK of AZD5213 after a single and multiple doses by assessment of Cmax.</measure>
    <time_frame>Range of Days 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the PK of AZD5213 after a single and multiple doses by assessment of fe.</measure>
    <time_frame>Range of Days 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the PK of AZD5213 after a single and multiple doses by assessment of CLR.</measure>
    <time_frame>Range of Days 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the PK of AZD5213 after a single and multiple doses by assessment of CL/F.</measure>
    <time_frame>Range of Days 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the PK of AZD5213 after a single and multiple doses by assessment of t1/2.</measure>
    <time_frame>Range of Days 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the PK of AZD5213 after a single and multiple doses by assessment of tmax.</measure>
    <time_frame>Range of Days 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the PK of AZD5213 after a single and multiple doses by assessment of AUC.</measure>
    <time_frame>Range of Days 1-12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each cohort will have 6 subjects that will receive AZD5213</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each cohort will have 2 subjects that will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5213</intervention_name>
    <description>Four increasing doses for young and two increasing doses for elderly subjects. Subject will receive single dose of AZD5213 oral solution (Day 1) and then start the once daily repeated doses from Day 3 to 12 for 10 days</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo solution, single dose (Day 1) and repeated dose from Day 3 to 12 for 10 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated, written informed consent prior to any study specific
             procedures

          -  Japanese healthy male subjects aged 20 to 45 years (young) and male and female
             subjects aged 65 to 80 years (elderly)

          -  Male subjects should be willing to use barrier contraception ie, condoms, from the
             first day of dosing until 3 months after the last dose of investigational product

          -  Have a body mass index (BMI) between 17 and 27 kg/m2 and weigh at least 45 kg and no
             more than 100 kg

          -  Clinically normal physical findings, supine BP, pulse rate, ECG and laboratory
             assessments in relation to age, as judged by the investigator(s)

        Exclusion Criteria:

          -  History of any clinically significant disease or disorder which, in the opinion of the
             investigator, may either put the subject at risk because of participation in the
             study, or influence the results or the subject's ability to participate in the study

          -  History or presence of gastrointestinal, hepatic or renal disease or any other
             condition known to interfere with absorption, distribution, metabolism or excretion of
             drugs

          -  History of previous or ongoing psychiatric disease/condition including psychosis,
             affective disorder, anxiety disorder, and personality disorder including borderline
             according to the criteria in the Diagnostic and Statistical Manual of Mental Disorders

          -  History of psychotic disorder among first degree relatives.

          -  History of use of antipsychotic, antidepressant or anxiolytic drugs, prescribed as
             well as non-prescribed use.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Märta Segerdahl, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D, Södertälje</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Akimasa Watanabe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyushu Clinical Pharmacology Research Clinic, Japan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Centre</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1315&amp;filename=D3030C00004_Clinical_Study_Report_Synopsis.pdf</url>
    <description>D3030C00004_Clinical_Study_Report_Synopsis.pdf</description>
  </link>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2011</study_first_submitted>
  <study_first_submitted_qc>April 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2011</study_first_posted>
  <last_update_submitted>January 27, 2015</last_update_submitted>
  <last_update_submitted_qc>January 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AZD5213</keyword>
  <keyword>safety</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>single dose</keyword>
  <keyword>repeated dose</keyword>
  <keyword>young</keyword>
  <keyword>elderly</keyword>
  <keyword>Japanese</keyword>
  <keyword>healthy subject</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

